How to tackle congestion in acute heart failure

Korean Journal of Internal Medicine

Volumn 33, Issue 3, 2018, Pages 462-473

  Martens, Pieter ^a,b   Mullens, Wilfried ^a,b  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Congestion; Heart failure

Indexed keywords

LOOP DIURETIC AGENT;

CARDIAC IMAGING; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DRUG EFFECT; HEART VENTRICLE OVERLOAD; HEART VOLUME; HUMAN; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SODIUM RESTRICTION; TREATMENT PLANNING; COMPLICATION; HEART FAILURE;

HEART FAILURE; HUMANS;

EID: 85047129401     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2017.355     Document Type: Review

References (75)

1. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009;53:557-573.
2. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-216.
3. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics: 2013 update. A report from the American Heart Association. Circulation 2013;127:e6-e245.
4. Fang J, Mensah GA, Croft JB, Keenan NL. Heart fail-ure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008;52:428-434.
5. Cotter G, Kaluski E, Stangl K, et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail 2004;6:601-609.
6. Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail 2010;16:922-930.
7. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-1331.
8. Massie BM, O'Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-1428.
9. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-2019.
10. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
11. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-869.
12. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-e239.
13. Kociol RD, McNulty SE, Hernandez AF, et al. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail 2013;6:240-245.
14. Mentz RJ, O'Connor CM. Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol 2016;13:28-35.
15. Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008;118:1433-1441.
16. Mullens W, Verbrugge FH, Nijst P, Tang WHW. Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. Eur Heart J 2017;38:1872-1882.
17. Nijst P, Verbrugge FH, Grieten L, et al. The pathophysiological role of interstitial sodium in heart failure. J Am Coll Cardiol 2015;65:378-388.
18. Gelman S. Venous function and central venous pressure: a physiologic story. Anesthesiology 2008;108:735-748.
19. Greenway CV. Role of splanchnic venous system in overall cardiovascular homeostasis. Fed Proc 1983;42:1678- 1684.
20. Miller WL, Mullan BP. Understanding the heterogeneity in volume overload and fluid distribution in decompensated heart failure is key to optimal volume management: role for blood volume quantitation. JACC Heart Fail 2014;2:298-305.
21. Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM. Patterns of weight change preceding hospitalization for heart failure. Circulation 2007;116:1549-1554.
22. Verbrugge FH, Dupont M, Steels P, et al. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol 2013;62:485-495.
23. Androne AS, Hryniewicz K, Hudaihed A, Mancini D, La-manca J, Katz SD. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol 2004;93:1254-1259.
24. Greenway CV, Lister GE. Capacitance effects and blood reservoir function in the splanchnic vascular bed during non-hypotensive haemorrhage and blood volume expan- sion in anaesthetized cats. J Physiol 1974;237:279-294.
25. Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail 2011;4:669-675.
26. Davis KL, Laine GA, Geissler HJ, Mehlhorn U, Brennan M, Allen SJ. Effects of myocardial edema on the development of myocardial interstitial fibrosis. Microcirculation 2000;7:269-280.
27. Desai KV, Laine GA, Stewart RH, et al. Mechanics of the left ventricular myocardial interstitium: effects of acute and chronic myocardial edema. Am J Physiol Heart Circ Physiol 2008;294:H2428-H2434.
28. Davis KL, Mehlhorn U, Laine GA, Allen SJ. Myocardial edema, left ventricular function, and pulmonary hypertension. J Appl Physiol (1985) 1995;78:132-137.
29. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589-596.
30. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009;53:582-588.
31. Nijst P, Martens P, Dupont M, Tang WHW, Mullens W. Intrarenal flow alterations during transition from euvolemia to intravascular volume expansion in heart failure patients. JACC Heart Fail 2017;5:672-681.
32. Adamson PB, Smith AL, Abraham WT, et al. Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device. Circulation 2004;110:2389-2394.
33. Mullens W, Abrahams Z, Skouri HN, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol 2008;51:300-306.
34. Colombo PC, Doran AC, Onat D, et al. Venous congestion, endothelial and neurohormonal activation in acute decompensated heart failure: cause or effect? Curr Heart Fail Rep 2015;12:215-222.
35. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005;294:1625-1633.
36. Drazner MH, Hamilton MA, Fonarow G, Creaser J, Flavell C, Stevenson LW. Relationship between right and left-sid-ed filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 1999;18:1126-1132.
37. Capomolla S, Ceresa M, Pinna G, et al. Echo-Doppler and clinical evaluations to define hemodynamic profile in patients with chronic heart failure: accuracy and influence on therapeutic management. Eur J Heart Fail 2005;7:624- 630.
38. Rohde LE, Palombini DV, Polanczyk CA, Goldraich LA, Clausell N. A hemodynamically oriented echocardiogra-phy-based strategy in the treatment of congestive heart failure. J Card Fail 2007;13:618-625.
39. Francis GS, Felker GM, Tang WH. A test in context: critical evaluation of natriuretic peptide testing in heart failure. J Am Coll Cardiol 2016;67:330-337.
40. Verbrugge FH, Grieten L, Mullens W. New insights into combinational drug therapy to manage congestion in heart failure. Curr Heart Fail Rep 2014;11:1-9.
41. Guyton AC, Prather J, Scheel K, McGehee J. Interstitial fluid pressure. IV. Its effect on fluid movement through the capillary wall. Circ Res 1966;19:1022-1030.
42. ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors AA. Diuretic response in acute heart fail-ure-pathophysiology, evaluation, and therapy. Nat Rev Cardiol 2015;12:184-192.
43. Fonarow GC, Corday E; ADHERE Scientific Advisory Committee. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 2004;9:179-185.
44. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797-805.
45. Matsue Y, Damman K, Voors AA, et al. Time-to-furose-mide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol 2017;69:3042- 3051.
46. Martens P, Verbrugge FH, Nijst P, Dupont M, Mullens W. Changes in loop diuretic dose and outcome after cardiac resynchronization therapy in patients with heart failure and reduced left ventricular ejection fractions. Am J Cardiol 2017;120:267-273.
47. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010;56:1527-1534.
48. Kim GH. Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am J Nephrol 2004;24:595- 605.
49. Verbrugge FH, Steels P, Grieten L, Nijst P, Tang WH, Mullens W. Hyponatremia in acute decompensated heart failure: depletion versus dilution. J Am Coll Cardiol 2015;65:480-492.
50. Martens P, Nijst P, Mullens W. Current approach to de-congestive therapy in acute heart failure. Curr Heart Fail Rep 2015;12:367-378.
51. Butler J, Anstrom KJ, Felker GM, et al. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol 2017;2:950-958.
52. Verbrugge FH, Dupont M, Bertrand PB, et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol 2015;70:265-273.
53. Martens P, Mathieu C, Verbrugge FH. Promise of SGLT2 inhibitors in heart failure: diabetes and beyond. Curr Treat Options Cardiovasc Med 2017;19:23.
54. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657.
55. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.
56. Costanzo MR, Ronco C, Abraham WT, et al. Extracorpo-real ultrafiltration for fluid overload in heart failure: current status and prospects for further research. J Am Coll Cardiol 2017;69:2428-2445.
57. Lala A, McNulty SE, Mentz RJ, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in acute decompensated Heart Failure (CARESS-HF). Circ Heart Fail 2015;8:741-748.
58. Costanzo MR, Stevenson LW, Adamson PB, et al. Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. JACC Heart Fail 2016;4:333-344.
59. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010;122:265-272.
60. Greene SJ, Gheorghiade M, Vaduganathan M, et al. Hae-moconcentration, renal function, and post-discharge out- comes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail 2013;15:1401-1411.
61. Testani JM, Brisco MA, Chen J, McCauley BD, Parikh CR, Tang WH. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol 2013;62:516-524.
62. van der Meer P, Postmus D, Ponikowski P, et al. The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol 2013;61:1973-1981.
63. Katz SD. In search of euvolemia in heart failure. JACC Heart Fail 2014;2:306-307.
64. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiol Pol 2016;74:1037-1147.
65. Mullens W, Abrahams Z, Francis GS, et al. Sodium nitro-prusside for advanced low-output heart failure. J Am Coll Cardiol 2008;52:200-207.
66. On bedresting in heart failure. Lancet 1990;336:975-976.
67. Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 2000;140:840- 847.
68. Morley D, Brozena SC. Assessing risk by hemodynamic profile in patients awaiting cardiac transplantation. Am J Cardiol 1994;73:379-383.
69. Singh A, Laribi S, Teerlink JR, Mebazaa A. Agents with vasodilator properties in acute heart failure. Eur Heart J 2017;38:317-325.
70. Packer M, O'Connor C, McMurray JJV, et al. Effect of ular-itide on cardiovascular mortality in acute heart failure. N Engl J Med 2017;376:1956-1964.
71. Verbrugge FH, Dupont M, Finucan M, et al. Response and tolerance to oral vasodilator up-titration after intravenous vasodilator therapy in advanced decompensated heart failure. Eur J Heart Fail 2015;17:956-963.
72. Stevenson LW, Zile M, Bennett TD, et al. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail 2010;3:580-587.
73. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 2013;61:391-403.
74. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical out- comes for patients hospitalized with heart failure. JAMA 2007;297:61-70.
75. Kula AJ, Hanberg JS, Wilson FP, et al. Influence of titra-tion of neurohormonal antagonists and blood pressure reduction on renal function and decongestion in decompensated heart failure. Circ Heart Fail 2016;9:e002333.